DNA repair by homologous recombination 1 is highly suppressed in G1 cells 2,3 to ensure that mitotic recombination occurs solely between sister chromatids 4 . Although many homologous recombination factors are cell-cycle regulated, the identity of the events that are both necessary and sufficient to suppress recombination in G1 cells is unknown. Here we report that the cell cycle controls the interaction of BRCA1 with PALB2-BRCA2 to constrain BRCA2 function to the S/G2 phases in human cells. We found that the BRCA1-interaction site on PALB2 is targeted by an E3 ubiquitin ligase composed of KEAP1, a PALB2-interacting protein 5 , in complex with cullin-3 (CUL3)-RBX1 (ref. 6). PALB2 ubiquitylation suppresses its interaction with BRCA1 and is counteracted by the deubiquitylase USP11, which is itself under cell cycle control. Restoration of the BRCA1-PALB2 interaction combined with the activation of DNA-end resection is sufficient to induce homologous recombination in G1, as measured by RAD51 recruitment, unscheduled DNA synthesis and a CRISPR-Cas9-based gene-targeting assay. We conclude that the mechanism prohibiting homologous recombination in G1 minimally consists of the suppression of DNA-end resection coupled with a multistep block of the recruitment of BRCA2 to DNA damage sites that involves the inhibition of BRCA1-PALB2-BRCA2 complex assembly. We speculate that the ability to induce homologous recombination in G1 cells with defined factors could spur the development of gene-targeting applications in non-dividing cells.
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The breast and ovarian tumour suppressors BRCA1, PALB2 and BRCA2 promote DNA double-strand break (DSB) repair by homologous recombination [7] [8] [9] . BRCA1 promotes DNA-end resection to produce the single-stranded (ss)DNA necessary for homology search and strand invasion 1 and it also interacts with PALB2 (refs 10-12) to direct the recruitment of BRCA2 (ref. 10) and RAD51 (refs 13 and 14) to DSB sites. The accumulation of BRCA1 on the chromatin that flanks DSB sites is suppressed in G1 cells 15 , reminiscent of the potent inhibition of homologous recombination in this phase of the cell cycle. Since the inhibition of BRCA1 recruitment in G1 is dependent on the 53BP1 and RIF1 proteins 15, 16 , two inhibitors of end resection [15] [16] [17] [18] [19] , this regulation of BRCA1 was originally viewed in light of its function in DNA-end processing.
However, as BRCA1 is also involved in promoting the recruitment of BRCA2 through its interaction with PALB2, we asked whether inducing BRCA1 recruitment to DSB sites in G1, through mutation of 53BP1 (also known as TP53BP1) by genome editing (53BP1Δ ; Extended Data Fig. 1a -c) also resulted in BRCA2 accumulation into ionizing-radiation-induced foci. To our surprise, and in contrast with BRCA1, we found that neither BRCA2 nor PALB2 are recruited to G1 DSB sites in U2OS cells lacking 53BP1 at ionizing radiation doses ranging from 2 to 20 Gy (Fig. 1a, b and Extended Data Fig. 1d , e).
Since BRCA1 and PALB2 interact directly 10, 11 , this result suggested that G1 cells may block BRCA2 recruitment by suppressing the BRCA1-PALB2 interaction. Indeed, while PALB2 interacts with BRCA2 irrespective of cell cycle position, it interacts efficiently with BRCA1 only during S phase (Fig. 1c) . The presence of DNA damage led to the loss of the residual PALB2-BRCA1 interaction in G1 whereas it had little impact on the assembly of the BRCA1-PALB2-BRCA2 complex in S phase (Fig. 1c) . Since all proteins were expressed in G1 (Fig. 1c) , our results suggest that the assembly of the BRCA1-PALB2-BRCA2 complex is controlled during the cell cycle, possibly to restrict the accumulation of BRCA2 at DSB sites to the S/G2 phases.
We confirmed these results using a single-cell assay assessing the colocalization, at an integrated lacO array 20 , of an mCherry-tagged LacR-BRCA1 fusion protein with GFP-tagged PALB2 (Extended Data Fig. 2a ). This LacR/lacO system recapitulated the cell-cycle-dependent and DNA-damage-sensitive BRCA1-PALB2 interaction (Extended Data Fig. 2b ) and enabled us to determine that sequences on PALB2, located outside its amino-terminal BRCA1-interaction domain (residues 1-50) were responsible for the cell-cycle-dependent regulation of its association with BRCA1 (Extended Data Fig. 2c, d ). Further deletion mutagenesis identified a single region, encompassed within residues 46-103 in PALB2 (Extended Data Fig. 2e , f) responsible for the cell-cycle-dependent regulation of the BRCA1-PALB2 interaction. This region corresponds to the interaction site for KEAP1 (ref. 5), identifying this protein as a candidate regulator of the BRCA1-PALB2 interaction.
KEAP1 is a substrate adaptor for a CUL3-RING ubiquitin (Ub) ligase (CRL3) that targets the antioxidant regulator NRF2 for proteasomal degradation 21 and recognizes an 'ETGE' motif on both PALB2 and NRF2 through its KELCH domain 5 . Depletion of KEAP1 from 53BP1Δ cells, or deletion of the ETGE motif in full-length PALB2 (PALB2 Δ ETGE) induced PALB2 ionizing-radiation-induced focus formation in G1 cells ( Fig. 1d and Extended Data Fig. 3a) . Furthermore, in cells in which KEAP1 was inactivated by genome editing (KEAP1Δ ; Extended Data Fig. 3b) we detected a stable BRCA1-PALB2-BRCA2 complex in both G1 and S phases (Fig. 1e) . KEAP1 is therefore an inhibitor of the BRCA1-PALB2 interaction.
CUL3 also interacts with PALB2 (Extended Data Fig. 3c ), and its depletion in 53BP1Δ U2OS cells de-repressed PALB2 ionizingradiation-induced foci in G1 (Fig. 1d and Extended Data Fig. 3a) . Furthermore, in G1-synchronized KEAP1Δ cells, expression of a CUL3-binding-deficient KEAP1 protein that lacks its BTB domain (Δ BTB) failed to suppress the BRCA1-PALB2 interaction, unlike its wild-type counterpart (Extended Data Fig. 3d ). These results suggest that KEAP1 recruits CUL3 to PALB2 to suppress its interaction with BRCA1.
Using the LacR/lacO system and co-immunoprecipitation assays, we found that a mutant of PALB2 lacking all eight lysine residues in the BRCA1-interaction domain (PALB2-KR; Fig. 2a ) could interact with BRCA1 irrespective of cell cycle position ( Fig. 2b and Extended Data Fig. 3e, f) . Further mutagenesis identified residues 20, 25 and 30 in PALB2 as critical for the suppression of the BRCA1-PALB2 interaction, since reintroduction of these lysines in the context of PALB2-KR (yielding PALB2-KR/K3; Fig. 2a ) led to the suppression of BRCA1-PALB2-BRCA2 complex assembly in G1 cells (Fig. 2b and Extended Data Fig. 3e ). Together, these results suggested a model whereby PALB2-bound KEAP1 forms an active CRL3 complex that ubiquitylates the PALB2 N terminus to suppress its interaction with BRCA1.
While PALB2 ubiquitylation can be detected in cells (Extended Data Fig. 4a ), the lysine-rich nature of the PALB2 N terminus has so far precluded us from unambiguously mapping in vivo ubiquitylation sites on Lys 20, 25 or 30. However, we could detect ubiquitylation on Lys 16 and Lys 43 by mass spectrometry, indicating that the PALB2 N terminus is ubiquitylated (Extended Data Fig. 4b ). In a complementary set of experiments, PALB2 targeted to the lacO array induced immunoreactivity to conjugated Ub (Extended Data Fig. 4c-e ). Ub colocalization with PALB2 was highest in G1, and depended on the KEAP1-interaction motif and the presence of the Lys 20/25/30 residues (Extended Data Fig. 4d-e) , consistent with the model that PALB2 is ubiquitylated on those sites in G1 cells. Indeed, we could readily reconstitute ubiquitylation of the N terminus of PALB2 (residues 1-103; fused to a haemagglutinin (HA) epitope tag), by recombinant CRL3-KEAP1, in a manner that depended on the KEAP1-interaction domain of PALB2 (Fig. 2c) , and we unambiguously identified Lys 25 and Lys 30 as being ubiquitylated by KEAP1 in vitro by mass spectrometry (Extended Data Fig. 5 ).
Ubiquitylation of PALB2 by CRL3-KEAP1 inhibited its interaction with a BRCA1 fragment comprising residues 1363-1437 (BRCA1-CC), an inhibition that was more obvious with the highly modified forms of PALB2 owing to the presence of ubiquitylated lysines outside the BRCA1-interaction domain (Fig. 2d) . To test specifically whether ubiquitylation of a single lysine residue (of the three identified as critical) inhibited the interaction with BRCA1, we used chemical crosslinking to install a single Ub moiety at position 20 or 45 (yielding PALB2-K C 20-Ub and PALB2-K C 45-Ub, respectively). Ubiquitylation of PALB2 at position 20 completely suppressed its interaction with BRCA1 whereas modification of residue 45 had no impact on the interaction (Extended Data Fig. 6a ), echoing the in vivo data (Extended Data  Fig. 3e ). Together, these results indicate that ubiquitylation of PALB2 at specific sites on its N terminus prevents its interaction with BRCA1. Since neither the activity of the CRL3-KEAP1 E3 ligase (Extended Data Fig. 6b ) nor the interaction of CRL3-KEAP1 with PALB2 (Extended Data Fig. 3c ) are regulated by the cell cycle, we considered the possibility that deubiquitylation of PALB2 might be regulated in a cell-cycle-dependent manner. KEAP1 physically interacts with USP11 (ref. 22), a deubiquitylase that also interacts with BRCA2 (ref. 23) and PALB2 (Extended Data Fig. 6c ). USP11 depletion impairs gene conversion 24 (Extended Data Fig. 6d ) and results in hypersensitivity to PARP inhibition 24 , identifying it as a homologous recombination regulator of unknown function. Co-immunoprecipitation experiments confirmed that USP11 and its catalytic activity were necessary for the formation of a stable BRCA1-PALB2-BRCA2 complex, especially in the presence of DNA damage ( Fig. 3a and Extended Data Fig. 6e, f) .
If USP11 antagonizes PALB2 ubiquitylation by CRL3-KEAP1, then removal of KEAP1 (or CUL3) should reverse the phenotypes imparted by loss of USP11. Indeed, deletion of KEAP1 restored resistance to PARP inhibitors (PARPi) and the BRCA1-PALB2 interaction in USP11-knockout cells prepared by genome editing (USP11Δ ; Fig. 3b , c and Extended Data Fig. 6e ). Likewise, depletion of CUL3 or KEAP1 reversed the gene conversion defect of USP11-depleted cells (Extended Data Fig. 7a) . Introduction of the PALB2-KR mutant restored its interaction with BRCA1 and reversed PARPi sensitivity in USP11Δ cells in a manner that depended on Lys 20/25/30 (Extended Data Fig. 7b, c) . Since recombinant USP11 can de-ubiquitylate PALB2 (1-103) in vitro (Fig. 3d) , these results suggest that USP11 promotes the assembly of the BRCA1-PALB2-BRCA2 complex by reversing the inhibitory ubiquitylation on the PALB2 Lys 20/25/30 residues.
We observed that USP11 turns over rapidly in G1 cells and interacts poorly with PALB2 in this phase of the cell cycle (Extended Data Fig. 8a, b) . Furthermore, there is a rapid loss of USP11 upon DNA damage induction, specifically in G1 phase ( Fig. 3e and Extended Data Fig. 8b, c) . The destabilization of USP11 after ionizing radiation treatment is dependent on ATM signalling, whereas it is ATR-dependent after ultraviolet irradiation (Extended Data Fig. 8d , e). The drop in USP11 steady-state levels in G1 is the result of proteasomal degradation (Extended Data Fig. 8f) . A CRL4 E3 Ub ligase is probably responsible for controlling the stability of USP11, as treatment with MLN4924, a pan-CRL inhibitor 25 (Extended Data Fig. 8g ), or depletion of CUL4 ( Fig. 3f) , protected USP11 from DNA-damage-induced degradation. CUL4 depletion led to BRCA2 and PALB2 ionizing-radiation-induced focus formation in G1 53BP1Δ cells ( Fig. 3g and Extended Data Fig. 9a ), consistent with the regulation of USP11 by a CRL4 complex acting as the upstream signal that ultimately controls BRCA1-PALB2-BRCA2 complex assembly.
While deletion of 53BP1 produces low levels of ssDNA in G1 cells 26 , combining the 53BP1Δ mutation with depletion of KEAP1 did not produce extraction-resistant RAD51 ionizing-radiation-induced foci, suggesting little-to-no RAD51 nucleofilament formation (Extended Data Fig. 9b ). We surmised that ssDNA formation remained insufficient in those cells and thus took advantage of the phosphomimetic T847E mutant of CtIP that promotes resection in G1 cells 27 . Unlike wildtype CtIP, introduction of CtIP(T847E) into 53BP1Δ cells depleted of KEAP1 induced RAD51 ionizing-radiation-induced focus formation in G1 cells ( To test whether productive homologous recombination could also be activated in G1, we employed a CRISPR-Cas9-stimulated genetargeting assay 28 in which the insertion of the coding sequence for the mClover fluorescent protein at the 5′ end of the lamin A (LMNA) or PML genes was monitored by microscopy or flow cytometry ( Fig. 4c and Extended Data Fig. 9e , f), with the latter method enabling the gating of cells with a defined DNA content (such as G1 cells). We also established synchronization protocols in which G1 cells obtained after release from a thymidine block were arrested in G1 by lovastatin treatment 2 for 24 h (Extended Data Fig. 9g, h ). Using this system, we determined a concentration of donor template in the linear range of the assay and ascertained that gene targeting at the LMNA locus was dependent on BRCA1-PALB2-BRCA2 complex assembly (Extended Data Fig. 10a, b) . We also confirmed that gene targeting by homologous recombination was highly suppressed in G1 (Fig. 4d) .
The combined activation of resection and BRCA1 recruitment to DSB sites (that is, in 53BP1Δ cells expressing CtIP(T847E)) was insufficient to stimulate gene targeting at either the LMNA or the PML locus in G1 cells ( Fig. 4e and Extended Data Fig. 10c, d ). However, when the BRCA1-PALB2 interaction was restored in resection-competent G1 cells using either KEAP1 depletion or expression of the PALB2-KR mutant, we detected a robust increase in gene-targeting events at both loci ( Fig. 4e and Extended Data Fig. 10c, d ). We note, however, that the gene-targeting frequencies of G1 cells remained lower than those of asynchronously dividing cells, suggesting an incomplete activation of homologous recombination. 53BP1 inactivation and the expression of CtIP(T847E) were both necessary for G1 homologous recombination (Extended Data Fig. 10e, f) , indicating that the simultaneous activation of end resection and BRCA2 recruitment to DSB sites were both necessary and sufficient to activate unscheduled recombination in this phase of the cell cycle. We conclude that the regulation of BRCA1-PALB2-BRCA2 complex assembly is a key node in the cell cycle control of DSB repair by homologous recombination. This regulation converges on the BRCA1-interaction site on PALB2 and is enforced by the opposing activities of the E3 ligase CRL3-KEAP1 and the deubiquitylase USP11, with the latter being antagonized in G1 by a CRL4 complex (Fig. 4f) . Our studies also demonstrate that the suppression of homologous recombination in G1 cells is largely reversible and that it involves the combined suppression of end resection and BRCA2 recruitment to DSB sites (Fig. 4f) . As most cells in the human body are not actively cycling and are thus refractory to homologous recombination, the manipulations described here may eventually enable therapeutic gene targeting in a wide variety of tissues. However, these approaches may necessitate the reversal of additional blocks to gene targeting such as the potential downregulation of homologous recombination factor expression in post-mitotic cells.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Letter reSeArCH using the EcoRI/XhoI sites. The coiled-coil domain of BRCA1 was cloned into pMAL-c2 using the BamHI/SalI sites. Truncated forms of PALB2 were obtained by introducing stop codons or deletions through site-directed mutagenesis. Fulllength CtIP was amplified by PCR, subcloned into the pDONR221 and delivered into the lentiviral construct pCW57.1 (a gift from D. Root; Addgene plasmid #41393) using Gateway cloning technology (Invitrogen). The USP11 cDNA was a gift from D. Cortez and was amplified by PCR and cloned into the pDsRed2-C1 vector using the EcoRI/SalI sites. The bacterial codon-optimized coding sequence of pig USP11 was subcloned into the 6× His-GST vector pETM-30-Htb using the BamHI/EcoRI sites. siRNA-resistant versions of PALB2, BRCA1 and USP11 constructs were generated as previously described 11 . Full-length CUL3 and RBX1 were amplified by PCR from a human pancreas cDNA library (Invitrogen) as previously described 30 and cloned into the dual expression pFBDM vector using NheI/XmaI and BssHII/NotI respectively. The NEDD8 cDNA was a gift from D. Xirodimas and was fused to a double StrepII tag at its C terminus in the pET17b vector (Millipore). Human DEN1 was amplified from a vector supplied by A. Echalier and fused to a non-cleavable N-terminal StrepII2× tag by PCR and inserted into a pET17b vector. The pCOOL-mKEAP1 plasmid was a gift from F. Shao. The pcDNA3-HA2-KEAP1 and pcDNA3-HA2-KEAP1Δ BTB were gifts from Y. Xiong (Addgene plasmids #21556 and 21593). gRNAs were synthesized and processed as described previously 31 . Annealed gRNAs were cloned into the Cas9-expressing vectors pSpCas9(BB)-2A-Puro (PX459) or pX330-U6-Chimeric_ BB-CBh-hSpCas9, a gift from F. Zhang (Addgene plasmids #48139 and 42230). The gRNAs targeting the LMNA or the PML locus and the mClover-tagged LMNA or PML are described previously 28 . The lentiviral packaging vector psPAX2 and the envelope vector VSV-G were a gift from D. Trono (Addgene plasmids #12260 and 12259). His 6 -Ub was cloned into the pcDNA5-FRT/TO backbone using the XhoI/ HindIII sites. All mutations were introduced by site-directed mutagenesis using QuikChange (Stratagene) and all plasmids were sequence-verified. Cell culture and plasmid transfection. All culture media were supplemented with 10% fetal bovine serum (FBS). U-2-OS (U2OS) cells were cultured in McCoy's medium (Gibco). 293T cells were cultured in DMEM (Gibco). Parental cells were tested for mycoplasma contamination and authenticated by STR DNA profiling. Plasmid transfections were carried out using Lipofectamine 2000 Transfection Reagent (Invitrogen) following the manufacturer's protocol. Lentiviral infection was carried out as previously described 15 . U2OS and 293T cells were purchased from ATCC. U2OS 256 cells were a gift from R. Greenberg. Antibodies. We employed the following antibodies: rabbit anti-53BP1 (A300-273A, Bethyl), rabbit anti-53BP1 (sc-22760, Santa Cruz), mouse anti-53BP1 (#612523, BD Biosciences), mouse anti-γ -H2AX (clone JBW301 , camptothecin (CPT; Sigma) at 0.2 µ M, ATM inhibitor (KU55933; Selleck Chemicals) at 10 µ M, ATR inhibitor (VE-821; a gift from P. Reaper) at 10 µ M, DNA-PKcs inhibitor (NU7441; Genetex) at 10 µ M, proteasome inhibitor MG132 (Sigma) at 2 µ M, lovastatin (S2061; Selleck Chemicals) at 40 µ M, doxycycline (#8634-1; Clontech), Nedd8-activating enzyme inhibitor (MLN4929; Active Biochem) at 5 µ M and olaparib (Selleck) at the indicated concentrations. Immunofluorescence microscopy. In most cases, cells were grown on glass coverslips, fixed with 2% (w/v) paraformaldehyde in PBS for 20 min at room temperature, permeabilized with 0.3% (v/v) Triton X-100 for 20 min at room temperature and blocked with 5% BSA in PBS for 30 min at room temperature. Alternatively, cells were fixed with 100% cold methanol for 10 min at − 20 °C and subsequently washed with PBS for 5 min at room temperature before PBS-BSA blocking. Cells were then incubated with the primary antibody diluted in PBS-BSA for 2 h at room temperature. Cells were next washed with PBS and then incubated with secondary antibodies diluted in PBS-BSA supplemented with 0.8 µ g ml −1 of DAPI to stain DNA for 1 h at room temperature. The coverslips were mounted onto glass slides with Prolong Gold mounting agent (Invitrogen). Confocal images were taken using a Zeiss LSM780 laser-scanning microscope. For G1 versus S/ G2 analysis of the BRCA1-PALB2-BRCA2 axis, cells were first synchronized with a double-thymidine block, released to allow entry into S phase and exposed to 2 or 20 Gy of X-irradiation at 5 h and 12 h post-release and fixed at 1 to 5 h post-treatment (where indicated). For the examination of DNA replication, cells were pre-incubated with 30 µ M BrdU for 30 min before irradiation and processed as previously described. CRISPR-Cas9 genome editing of USP11/KEAP1. 293T and U2OS cells were transiently transfected with three distinct sgRNAs targeting either 53BP1, USP11 or KEAP1 and expressed from the pX459 vector containing Cas9 followed by the 2A-Puromycin cassette. The next day, cells were selected with puromycin for 2 days and subcloned to form single colonies or subpopulations. Clones were screened by immunoblot and/or immunofluorescence to verify the loss of 53BP1, USP11 or KEAP1 expression and subsequently characterized by PCR and sequencing. The genomic region targeted by the CRISPR-Cas9 was amplified by PCR using Turbo Pfu polymerase (Agilent) and the PCR product was cloned into the pCR2.1 TOPO vector (Invitrogen) before sequencing. Olaparib clonogenic assay. 293T cells were incubated with the indicated doses of olaparib (Selleck Chemicals) for 24 h, washed once with PBS and counted by trypan blue staining. Five-hundred cells were then plated in duplicate for each condition. The cell survival assay was performed as previously described 33 . Recombinant protein production. GST and MBP fusions proteins were produced as previously described 34, 35 . Briefly, MBP proteins expressed in Escherichia coli were purified on amylose resin (New England Biolabs) according to the batch method described by the manufacturer and stored in 1× PBS, 5% glycerol. GST proteins expressed in E. coli were purified on glutathione sepharose 4B (GE Healthcare) resin in 50 mM Tris HCl pH 7.5, 300 mM NaCl, 2 mM dithiothreitol (DTT), 1 mM EDTA, 15 µ g ml −1 AEBSF and 1× complete protease inhibitor cocktail (Roche). Upon elution from the resin using 50 mM glutathione in 50 mM Tris HCl pH 8, 2 mM DTT, the His 6 -GST tag was cleaved off using His-tagged TEV protease (provided by F. Sicheri) in 50 mM Tris HCl pH 7.5, 150 mM NaCl, 10 mM glutathione, 10% glycerol, 2 mM sodium citrate and 2 mM β -mercaptoethanol. His 6 -tagged proteins were depleted using Ni-NTA-agarose beads (Qiagen) in 50 mM Tris HCl pH 7.5, 300 mM NaCl, 20 mM imidazole, 5 mM glutathione, 10% glycerol, 1 mM sodium citrate and 2 mM β -mercaptoethanol followed by centrifugal concentration (Amicon centrifugal filters, Millipore). GST-mKEAP1 was purified as described previously 36 , with an additional anion exchange step on a HiTrap Q HP column (GE Healthcare). The GST tag was left on the protein for in vitro experiments. Purification of CUL3 and RBX1 was performed as previously described 30 . NEDD8 (gift from D. Xirodimas) and DEN1 were expressed in E. coli BL21 grown in Terrific broth media and induced overnight with 0.5 mM isopropyl-β -d-thiogalactoside (IPTG) at 16 °C. Cells were harvested and resuspended in wash buffer (400 mM NaCl, 50 mM Tris-HCl, pH 8, 5% glycerol, 2 mM DTT), supplemented with lysozyme, universal nuclease (Pierce), benzamidine, leupeptin, pepstatin, PMSF and complete protease inhibitor cocktail (Roche), except for DEN1-expressing cells where the protease inhibitors were omitted. Cells were lysed by sonication and the lysate was cleared by centrifugation at 20,000 r.p.m. for 50 min. The soluble supernatant was bound to a 5 ml StrepTactin Superflow Cartridge with a flow rate of 3 ml min −1 using a peristaltic pump.
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The column was washed with 20 column volumes (CV) of washing buffer and eluted with 5 CV washing buffer, diluted 1:2 in water to reduce the final salt concentration, and supplemented with 2.5 mM desthiobiotin. The elution fractions were pooled and concentrated to a total volume of 4 ml using a 3 kDa cut-off Amicon concentrator. DEN1 was further purified over a Superdex 75 size-exclusion column, buffer exchanged into 150 mM NaCl, HEPES, pH 7.6, 2% glycerol and 1 mM DTT. The C-terminal pro-peptide and StrepII2× -tag were removed by incubation with StrepII2× -DEN1 in a 1:20 molar ratio for 1 h at room temperature. The DEN1 cleavage reaction was buffer exchanged on a Zeba MWCO desalting column (Pierce), to remove the desthiobiotin, and passed through a Strep-Tactin Cartridge, which retains the C-terminal pro-peptide and DEN1. The GST-tagged Sus scrofa (pig) USP11 proteins were expressed in E. coli as described 37 . Cells were lysed by lysozyme treatment and sonication in 50 mM Tris pH 7.5, 300 mM NaCl, 1 mM EDTA, 1 mM AEBSF, 1× Protease Inhibitor mix (284 ng ml −1 leupeptin, 1.37 µ g ml −1 pepstatin A, 170 µ g ml −1 PMSF and 330 µ g ml −1 benzamidine) and 5% glycerol. Cleared lysate was applied to a column packed with glutathione sepharose 4B (GE Healthcare), washed extensively with lysis buffer before elution in 50 mM Tris pH 7.5, 150 mM NaCl, 5% glycerol and 25 mM reduced glutathione. DUB activity was assayed on fluorogenic ubiquitin-AMC (Enzo life sciences), measured using a Synergy Neo microplate reader (Biotek). His 6 -TEV-ubiquitin-G76C was purified on chelating HiTrap resin, following the manufacturer's instructions, followed by size-exclusion chromatography on a S-75 column (GE healthcare). The protein was extensively dialysed in 1 mM acetic acid and lyophilized. In vitro ubiquitylation and deubiquitylation of PALB2. HA-tagged N-terminal fragments of PALB2 (1-103) (1 µ M) were in vitro ubiquitylated using 50 µ M wild-type (Ubi WT, Boston Biochem) or a lysine-less ubiquitin (Ub-K0, Boston Biochem), 100 nM human UBA1 (E1), 500 nM CDC34 (provided by F. Sicheri and D. Ceccarelli), 250 nM neddylated CUL3/RBX1, 375 nM GST-mKEAP1 and 1.5 mM ATP in a buffer containing 50 mM Tris HCl pH 7.5, 20 mM NaCl, 10 mM MgCl 2 and 0.5 mM DTT. Ubiquitylation reactions were carried out at 37 °C for 1 h, unless stated otherwise. For USP11-mediated deubiquitylation assays, HA-PALB2 (1-103) was first ubiquitylated using lysine-less ubiquitin with enzyme concentrations as described earlier in 50 µ l reactions in a buffer containing 25 mM HEPES pH 8, 150 mM NaCl, 10 mM MgCl 2 , 0.5 mM DTT and 1.5 mM ATP for 1.5 h at 37 °C. Reactions were stopped by the addition of 1 unit Apyrase (New England Biolabs). Reaction products were mixed at a 1:1 ratio with wild-type or catalytically inactive (C270S) USP11, or USP2 (provided by F. Sicheri and E. Zeqiraj) using final concentrations of 100 nM, 500 nM and 2,500 nM (USP11) and 500 nM (USP2) and incubated for 2 h at 30 °C in a buffer containing 25 mM HEPES pH 8, 150 mM NaCl, 2 mM DTT, 0.1 mg ml −1 BSA, 0.03% Brij-35, 5 mM MgCl 2 , 0.375 mM ATP. Pulldown experiments between purified PALB2 and BRCA1. PALB2 in vitro ubiquitylation reaction products were diluted in a buffer at final concentration of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 0.25 mM DTT and 0.1% NP-40. Twenty micrograms MBP or MBP-BRCA1-CC was coupled to amylose resin (New England Biolabs) in the above buffer supplemented with 0.1% BSA before addition of the ubiquitylation products. Pulldown reactions were performed at 4 °C for 2 h, followed by extensive washing. Co-immunoprecipitation. Cells were collected by trypsinization, washed once with PBS and lysed in 500 µ l of lysis buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM EDTA, 1% NP-40, complete protease inhibitor cocktail (Roche), cocktail of phosphatase inhibitors (Sigma) and N-ethylmaleimide to inhibit deubiquitylation) on ice. Lysates were centrifuged at 15,000g for 10 min at 4 °C and protein concentration was evaluated using absorbance at 280 nm. Equivalent amounts of proteins (∼0.5-1 mg) were incubated with 2 µ g of rabbit anti-PALB2, rabbit anti-USP11 antibody, rabbit anti-GFP antibody or normal rabbit IgG for 5 h at 4 °C. A mix of protein A/protein G-Sepharose beads (Thermo Scientific) was added for an additional hour. Beads were collected by centrifugation, washed twice with lysis buffer and once with PBS, and eluted by boiling in 2× Laemmli buffer before analysis by SDS-PAGE and immunoblotting. For mass spectrometry analysis of Flag-PALB2, 150 × 10 6 transiently transfected HEK293T cells were lysed in high-salt lysis buffer (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM EDTA, 1% Triton X-100, 3 mM MgCl 2 , 3 mM CaCl 2 ), supplemented with complete protease inhibitor cocktail (Roche), 4 mM 1,10-Phenantroline, 50 U benzonase and 50 U micrococcal nuclease. Cleared lysates were incubated with Flag-M2 agarose (Sigma), followed by extensive washing in lysis buffer and 50 mM ammoniumbicarbonate. Mass spectrometry. After immunoprecipitation of transiently transfected Flag-PALB2 from siCTRL-transfected or USP11 siRNA-depleted 293T cells, cysteine residues were reduced and alkylated on beads using 10 mM DTT (30 min at 56 °C) and 15 mM 2-chloroacetamide (1 h at room temperature), respectively. Proteins were digested using limited trypsin digestion on beads (1 µ g trypsin; Worthington) per sample, 20 min at 37 °C), and dried to completeness. For LC-MS/MS analysis, peptides were reconstituted in 5% formic acid and loaded onto a 12 cm fused silica column with pulled tip packed in-house with 3.5 µ m Zorbax C18 (Agilent Technologies). Samples were analysed using an Orbitrap Velos (Thermo Scientific) coupled to an Eksigent nanoLC ultra (AB SCIEX). Peptides were eluted from the column using a 90 min linear gradient from 2% to 35% acetonitrile in 0.1% formic acid. Tandem MS spectra were acquired in a data-dependent mode for the top two most abundant multiply charged peptides and included targeted scans for five specific N-terminal PALB2 tryptic digest peptides (charge state 1+ , 2+ , 3+ ), either in non-modified form or including a diGly-ubiquitin trypsin digestion remnant. Tandem MS spectra were acquired using collision-induced dissociation. Spectra were searched against the human Refseq_V53 database using Mascot, allowing up to four missed cleavages and including carbamidomethyl (C), deamidation (NQ), oxidation (M), GlyGly (K) and LeuArgGlyGly (K) as variable modifications.
In vitro ubiquitylated HA-PALB2 (1-103) (50 µ l total reaction mix) was run briefly onto an SDS-PAGE gel, followed by total lane excision, in-gel reduction using 10 mM DTT (30 min at 56 °C), alkylation using 50 mM 2-chloroacetamide and trypsin digestion for 16 h at 37 °C. Digested peptides were mixed with 20 µ l of a mix of 10 unique heavy isotope-labelled N-terminal PALB2 (AQUA) peptides (covering full or partial tryptic digests of regions surrounding Lys 16, 25, 30 or 43, either in non-modified or diG-modified form; 80-1,200 fmol µ l −1 per peptide, based on individual peptide sensitivity testing) before loading 6 µ l onto a 12 cm fused silica column with pulled tip packed in-house with 3.5 µ m Zorbax C18. Samples were measured on an Orbitrap ELITE (Thermo Scientific) coupled to an Eksigent nanoLC ultra (AB SCIEX). Peptides were eluted from the column using a 180 min linear gradient from 2% to 35% acetonitrile in 0.1% formic acid. Tandem MS spectra were acquired in a data-dependent mode for the top two most abundant multiply charged ions and included targeted scans for the ten specific N-terminal PALB2 tryptic digest peptides (charge states 1+ , 2+ , 3+ ), either in light or heavy isotope-labelled form. Tandem MS spectra were acquired using collision induced dissociation. Spectra were searched against the human Refseq_V53 database using Mascot, allowing up to two missed cleavages and including carbamidomethyl (C), deamidation (NQ), oxidation (M), GlyGly (K) and LeuArgGlyGly (K) as variable modifications, after which spectra were manually validated. His-Ub pulldown. 293 FLIP-IN cells stably expressing His 6 -Ub were transfected with the indicated siRNA and treated with doxycycline (DOX) for 24 h to induce His 6 -Ub expression. Cells were pre-treated with 10 mM N-ethylmaleimide for 30 min and lysed in denaturating lysis buffer (6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM Tris-HCl, 5 mM imidazole, 0.01 M β -mercaptoethanol, complete protease inhibitor cocktail). Lysates were sonicated on ice twice for 10 s with 1 min break and centrifuged at 15,000g for 10 min at 4 °C. The supernatant was incubated with Ni-NTA-agarose beads (Qiagen) for 4 h at 4 °C. Beads were collected by centrifugation, washed once with denaturating lysis buffer, once with wash buffer (8 M urea, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 10 mM Tris-HCl, 5 mM imidazole, 0.01 M β -mercaptoethanol, complete protease inhibitor cocktail), and twice with wash buffer supplemented with 0.1% Triton X-100, and eluted in elution buffer (0.2 M imidazole, 0.15 M Tris-HCl, 30% glycerol, 0.72 M β -mercaptoethanol, 5% SDS) before analysis by SDS-PAGE and immunoblotting. Homologous-recombination-based repair assays. Parental U2OS cells and U2OS cells stably expressing wild-type CtIP or CtIP(T847E) mutant were transfected with the indicated siRNA and the PALB2-KR construct, synchronized with a single thymidine block, treated with doxycycline to induce CtIP expression and subsequently blocked in G1 phase by adding 40 µ M lovastatin. Cells were collected by trypsinization, washed once with PBS and electroporated with 2.5 µ g of sgRNA plasmid and 2.5 µ g of donor template using the Nucleofector technology (Lonza; protocol X-001). Cells were plated in medium supplemented with 40 µ M lovastatin and grown for 24 h before flow cytometry analysis. PALB2 chemical ubiquitylation. PALB2 (1-103) polypeptides, engineered with only one cross-linkable cysteine, were ubiquitylated by cross-linking alkylation, as previously described 38, 39 , with the following modifications. Purified PALB2 cysteine mutant (final concentration of 600 µ M) was mixed with His 6 -TEVubiquitin G76C (350 µ M) in 300 mM Tris pH 8.8, 120 mM NaCl and 5% glycerol. Tris(2-carboxyethyl)phosphine (TCEP) (Sigma-Aldrich) reducing agent was added to a final concentration of 6 mM to the mixture and incubated for 30 min at room temperature. The bi-reactive cysteine cross-linker, 1,3-dichloroacetone (SigmaAldrich), was dissolved in dimethylformamide and added to the protein mix to a final concentration of 5.25 mM. The reaction was allowed to proceed on ice for 1 h, before being quenched by the addition of 5 mM β -mercaptoethanol. His 6 -TEV-ubiquitin-conjugated PALB2 was enriched by passing over Ni-NTA-agarose beads (Qiagen). Statistics and randomization. No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. and 53BP1Δ and U2OS cells were mock-or X-irradiated (10 Gy) before being processed for 53BP1 fluorescence microscopy. DAPI was used to stain DNA and trace the outline of the nucleus. c, Wild-type and 53BP1Δ U2OS cells were processed for 53BP1 immunoblotting. Tubulin was used as a loading control. d, Wild-type and 53BP1Δ U2OS cells either synchronized in G1 following a double-thymidine block and release or asynchronously dividing (ASN), were irradiated (2 Gy) and processed for γ -H2AX, PALB2, BRCA2 and BRCA1 immunofluorescence. The micrographs relating to BRCA1 and BRCA2 staining in G1 are found in Fig. 1a . e, Wild-type and 53BP1Δ U2OS cells synchronized in G1 after release from a doublethymidine block were irradiated (20 Gy) and processed for γ -H2AX, BRCA1 and BRCA2 immunofluorescence. On the left are representative micrographs for the G1-arrested cells and the quantitation of the full experiment is shown on the right (mean ± s.d., N = 3). 
